ND
Naval Daver
The University of Texas MD Anderson Cancer Center, Baylor College of Medicine
Research areas: Medicine · Hematology · Acute Myeloid Leukemia Research · Retinoids in leukemia and cellular processes · Chronic Myeloid Leukemia Treatments
0000-0001-7103-373X
Employment
-
The University of Texas MD Anderson Cancer Center Professor of Medicine2023 - Present
-
The University of Texas MD Anderson Cancer Center Associate Professor2017 - 2023
-
The University of Texas MD Anderson Cancer Center Assistat Professor2011 - 2017
Education
-
Baylor College of Medicine Fellowship - Oncology-Hematology2008 - 2011
-
Baylor College of Medicine Internal Medicine Residency2005 - 2008
-
Baylor College of Medicine Research Fellowship2004 - 2005
Projects & Funding
Projects & funding information is unavailable.
Publications (268)
- CPX-351 plus gemtuzumab ozogamicin in relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome Save
- Combination therapy with nelarabine, pegaspargase, and venetoclax for adult patients with R/R T-cell ALL/LBL Save
- Clinical characteristics of secondary myeloid neoplasms in patients with inflammatory bowel disease Save
- An all-oral triplet regimen (decitabine/cedazuridine, venetoclax, and gilteritinib) for newly diagnosed and relapsed/refractory FLT3-mutated AML and high-risk MDS Save
- Outcomes of adult patients with Li‐Fraumeni syndrome and myeloid neoplasms Save
- Phase 1 dose escalation and expansion trial of the bispecific CD47 inhibitor and CD40 agonist Fc‐fusion protein SL‐172154 (SIRPα‐Fc‐CD40L) in patients with higher‐risk myelodysplastic syndrome or acute myeloid leukemia Save
- Data from Investigational Clinical Trial Agents versus Conventional Second Salvage Therapies in Patients with Relapsed/Refractory Acute Myeloid Leukemia Save
- Investigational Clinical Trial Agents versus Conventional Second Salvage Therapies in Patients with Relapsed/Refractory Acute Myeloid Leukemia Save
- Supplementary Data 1 from Investigational Clinical Trial Agents versus Conventional Second Salvage Therapies in Patients with Relapsed/Refractory Acute Myeloid Leukemia Save
- Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study Save
- Long-term outcomes of azacitidine, venetoclax, and gilteritinib in newly diagnosed FLT3-mutated AML Save
- Microclone with megaimpact Save
- Data from Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial Save
- Data from Phase 1 Study of KITE-222, an Autologous CLL-1–Directed CAR T-cell Therapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia Save
- Figure S1 from Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial Save
- Figure S10 from Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial Save
- Figure S11 from Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial Save
- Figure S12 from Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial Save
- Figure S13 from Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial Save
- Figure S14 from Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial Save